pRDA_355
(Plasmid
#187159)
-
Purpose(Empty Backbone) Lentiviral expression of doxycycline inducible customizable Sp Cas9 sgRNA
-
Depositing Labs
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 187159 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 | |
This material is available to academics and nonprofits only.
Backbone
-
Vector backbonepRDA_355
-
Vector typeMammalian Expression, Lentiviral, CRISPR
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Cloning Information
- Cloning method Restriction Enzyme
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pRDA_355 was a gift from John Doench & David Root (Addgene plasmid # 187159 ; http://n2t.net/addgene:187159 ; RRID:Addgene_187159) -
For your References section:
Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. Aquilanti E, Kageler L, Watson J, Baird DM, Jones RE, Hodges M, Szegletes ZM, Doench JG, Strathdee CA, Figueroa JRMF, Ligon KL, Beck M, Wen PY, Meyerson M. Neuro Oncol. 2023 Jul 6;25(7):1275-1285. doi: 10.1093/neuonc/noad024. 10.1093/neuonc/noad024 PubMed 36694348
